Engineered immune cells target Tough-to-Treat blood cancers in new trial

NCT ID NCT03690011

Recruiting now Disease control Sponsor: Baylor College of Medicine Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated Apr 12, 2026 · Updated 23 times

Summary

This early-stage study is testing a new cell therapy for people with aggressive T-cell leukemias or lymphomas that have come back or not responded to other treatments. Doctors take a patient's own immune cells, modify them in a lab to better target cancer cells, and infuse them back. The main goal is to see if this approach is safe and to find the right dose, with the hope it will shrink tumors enough for patients to later receive a stem cell transplant.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for T-CELL ACUTE LYMPHOBLASTIC LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Houston Methodist Hospital
RECRUITING

Houston, Texas, 77030, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••
Texas Children's Hospital
RECRUITING

Houston, Texas, 77030, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA T-CELL ACUTE LYMPHOBLASTIC LYMPHOMA T-NON-HODGKIN LYMPHOMA